Danaher Corporation vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Danaher Corporation trades at $218.41 (market cap $152.87B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.03 (market cap $323.80B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 2.1× Danaher Corporation's market cap, and Danaher Corporation pays a 0.74% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Vanguard Tax Managed Fund FTSE Developed Markets ETF for 131 Days on average.
| DHR | VEA | |
|---|---|---|
Market Cap | $152.87B | $323.80B |
Volume | 5,228,698 | 17,001,112 |
Sector | Health | — |
52-Week High | $242.05 | $73.79 |
52-Week Low | $161.91 | $58.90 |
Typical Hold Time | 69 Days | 131 Days |
Enterprise Value | $175.08B | — |
Dividend Yield | 0.74% | — |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
Vanguard FTSE Developed Markets ETF (VEA) trades at $70.26, down 1.2% today, with a bearish technical signal from moving averages. The ETF offers exposure to developed markets outside the U.S. with a low 0.03% expense ratio and a recent dividend declared for September 2026. Recent news highlights its cost advantage over peers and mixed institutional activity, with some firms increasing stakes while others reduced positions.
VEA provides diversified international exposure at minimal cost, but near-term technical weakness and reliance on global economic stability pose risks. The fund's appeal lies in its efficiency and yield, yet investors face currency and geopolitical uncertainties inherent in non-U.S. markets. Long-term prospects depend on sustained growth in developed economies.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →